Artia Global Partners
Latest statistics and disclosures from Artia Global Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Lilly Eli & Co option, NVO, LLY, MRK, VKTX, and represent 67.52% of Artia Global Partners's stock portfolio.
- Added to shares of these 10 stocks: Lilly Eli & Co option (+$58M), VRTX (+$12M), ITCI (+$12M), MRK (+$6.6M), IRON (+$5.4M), VKTX, CYTK, CRNX, APGE, DYN.
- Started 24 new stock positions in Effector Therapeutics, CRNX, XENE, IDYA, LRMR, VRTX, SLN, MDGL, DYN, JANX. MREO, SLNO, ANNX, KURA, VERA, MRUS, ASND, ARVN, ALPN, MGNX, IRON, NAMS, PSTX, SWTX.
- Reduced shares in these 7 stocks: Cytokinetics (-$34M), Cytokinetics (-$33M), NVO, , WAT, Structure Therapeutics, TYRA.
- Sold out of its positions in BMRN, Cytokinetics, Cytokinetics, Structure Therapeutics, TYRA, WAT.
- Artia Global Partners was a net buyer of stock by $73M.
- Artia Global Partners has $498M in assets under management (AUM), dropping by 44.74%.
- Central Index Key (CIK): 0001937964
Tip: Access up to 7 years of quarterly data
Positions held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Artia Global Partners
Artia Global Partners holds 49 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co Put Put Option | 18.0 | $90M | +187% | 115k | 777.96 |
|
| Novo-nordisk A S Adr (NVO) | 17.9 | $89M | -4% | 692k | 128.40 |
|
| Eli Lilly & Co. (LLY) | 14.5 | $72M | 93k | 777.96 |
|
|
| Merck & Co (MRK) | 10.1 | $50M | +15% | 379k | 131.95 |
|
| Viking Therapeutics (VKTX) | 7.1 | $36M | +13% | 434k | 82.00 |
|
| Abbvie (ABBV) | 3.3 | $17M | 91k | 182.10 |
|
|
| Intra Cellular Therapies (ITCI) | 2.9 | $15M | +405% | 210k | 69.20 |
|
| Argenx Se Sponsored Adr (ARGX) | 2.7 | $14M | 34k | 393.72 |
|
|
| Astrazeneca Sponsored Adr (AZN) | 2.6 | $13M | 191k | 67.75 |
|
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.4 | $12M | NEW | 29k | 418.01 |
|
| Axsome Therapeutics (AXSM) | 1.4 | $7.0M | 88k | 79.80 |
|
|
| Ocular Therapeutix (OCUL) | 1.3 | $6.6M | +64% | 725k | 9.10 |
|
| Cytokinetics Com New (CYTK) | 1.3 | $6.3M | +178% | 90k | 70.11 |
|
| Neurocrine Biosciences (NBIX) | 1.2 | $6.2M | 45k | 137.92 |
|
|
| Disc Medicine (IRON) | 1.1 | $5.4M | NEW | 87k | 62.26 |
|
| Vaxcyte (PCVX) | 1.0 | $5.2M | +97% | 76k | 68.31 |
|
| Apogee Therapeutics (APGE) | 0.8 | $4.1M | +493% | 62k | 66.45 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.8 | $4.0M | NEW | 86k | 46.81 |
|
| Protagonist Therapeutics (PTGX) | 0.7 | $3.6M | +10% | 124k | 28.93 |
|
| Dyne Therapeutics (DYN) | 0.7 | $3.4M | NEW | 120k | 28.39 |
|
| Insmed Com Par $.01 (INSM) | 0.6 | $3.2M | +57% | 118k | 27.13 |
|
| Springworks Therapeutics (SWTX) | 0.5 | $2.7M | NEW | 54k | 49.22 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.5 | $2.4M | NEW | 16k | 151.17 |
|
| Ideaya Biosciences (IDYA) | 0.5 | $2.3M | NEW | 53k | 43.88 |
|
| Merus N V (MRUS) | 0.5 | $2.3M | NEW | 50k | 45.03 |
|
| Verona Pharma Sponsored Ads (VRNA) | 0.4 | $2.1M | 131k | 16.09 |
|
|
| Alpine Immune Sciences (ALPN) | 0.4 | $2.0M | NEW | 52k | 39.64 |
|
| Charles River Laboratories (CRL) | 0.4 | $1.9M | 6.9k | 270.95 |
|
|
| Janux Therapeutics (JANX) | 0.4 | $1.8M | NEW | 48k | 37.65 |
|
| Soleno Therapeutics (SLNO) | 0.4 | $1.8M | NEW | 41k | 42.80 |
|
| Xenon Pharmaceuticals (XENE) | 0.3 | $1.7M | NEW | 40k | 43.05 |
|
| Arvinas Ord (ARVN) | 0.3 | $1.7M | NEW | 40k | 41.28 |
|
| Pliant Therapeutics (PLRX) | 0.3 | $1.5M | 100k | 14.90 |
|
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.3 | $1.4M | NEW | 421k | 3.30 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.3 | $1.3M | NEW | 54k | 23.65 |
|
| Rapt Therapeutics (RAPT) | 0.2 | $1.2M | +599% | 137k | 8.98 |
|
| Silence Therapeutics Ads (SLN) | 0.2 | $1.1M | NEW | 53k | 21.60 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.2 | $1.1M | +3% | 52k | 20.67 |
|
| Annexon (ANNX) | 0.2 | $1.1M | NEW | 148k | 7.17 |
|
| Vera Therapeutics Cl A (VERA) | 0.2 | $1.0M | NEW | 24k | 43.12 |
|
| Macrogenics (MGNX) | 0.2 | $942k | NEW | 64k | 14.72 |
|
| Kura Oncology (KURA) | 0.2 | $842k | NEW | 40k | 21.33 |
|
| Immunovant (IMVT) | 0.1 | $691k | 21k | 32.31 |
|
|
| Biomea Fusion (BMEA) | 0.1 | $530k | +39% | 36k | 14.95 |
|
| Larimar Therapeutics (LRMR) | 0.1 | $442k | NEW | 58k | 7.59 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.1 | $416k | NEW | 1.6k | 267.04 |
|
| Effector Therapeutics Call Call Option | 0.1 | $360k | NEW | 25k | 14.39 |
|
| Poseida Therapeutics I (PSTX) | 0.1 | $274k | NEW | 86k | 3.19 |
|
| Gritstone Oncology Ord (GRTS) | 0.0 | $245k | 95k | 2.57 |
|
Past Filings by Artia Global Partners
SEC 13F filings are viewable for Artia Global Partners going back to 2022
- Artia Global Partners 2024 Q1 filed May 15, 2024
- Artia Global Partners 2023 Q4 filed Feb. 14, 2024
- Artia Global Partners 2023 Q3 filed Nov. 14, 2023
- Artia Global Partners 2023 Q2 filed Aug. 14, 2023
- Artia Global Partners 2023 Q1 filed May 15, 2023
- Artia Global Partners 2022 Q4 filed Feb. 14, 2023